Down-regulation of MSH3 and MSH6 genes in female breast cancer patients receiving taxane-based therapy
Abstract Background The DNA in each cell in our body is constantly in danger of becoming damaged. Most DNA damage gets repaired straight away via many different proteins encoded by DNA—repair genes. MSH3 and MSH6 are pivotal DNA repair genes maintaining human genome integrity. Dysregulated expressio...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SpringerOpen
2023-10-01
|
| Series: | Future Journal of Pharmaceutical Sciences |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s43094-023-00549-2 |
| _version_ | 1797637076928167936 |
|---|---|
| author | Hanaa R. M. Attia Dina F. Ayoub Shereen H. Abd El-Aziz Mai M. Abdel Wahed Safa N. Abd El-Fattah Mahmoud A. Abdel-Monem Thanaa M. Rabah Mahmoud M. Kamel Amany Helal Mona Hamed Ibrahim |
| author_facet | Hanaa R. M. Attia Dina F. Ayoub Shereen H. Abd El-Aziz Mai M. Abdel Wahed Safa N. Abd El-Fattah Mahmoud A. Abdel-Monem Thanaa M. Rabah Mahmoud M. Kamel Amany Helal Mona Hamed Ibrahim |
| author_sort | Hanaa R. M. Attia |
| collection | DOAJ |
| description | Abstract Background The DNA in each cell in our body is constantly in danger of becoming damaged. Most DNA damage gets repaired straight away via many different proteins encoded by DNA—repair genes. MSH3 and MSH6 are pivotal DNA repair genes maintaining human genome integrity. Dysregulated expression of such genes has its implications resulting in developing of adverse reactions in cancer breast patients receiving taxanes. Cancer chemotherapy with some of taxane class of agents are associated with significant neurotoxicity, arthralgias and myalgias that may offset the therapeutic benefits of taxane use. Our aim is to identify gene expression pattern of MSH3 and MSH6 DNA mismatch repair genes in female breast cancer patients who develop adverse reactions to taxane-based therapy. One hundred and five patients with histologically proven breast cancer who received paclitaxel (PTX) as a single agent or combination therapy have been enrolled along with a group of 50 females with benign breast lesions serving as controls.Gene expression studies of mismatch repair genes (MMR) genes; MSH3 and MSH6; have been performed by real-time PCR. Patients were divided into groups according to the determined type/grade of PTX-based toxicity and fold changes of both genes were estimated. Results In the present work both MMR genes showed significantly lower expression in all the studied patients compared to benign cases as a control group. Toxicity findings were encountered in 75.2% of the studied patient cohort. The most common observed type of toxicity was peripheral neuropathy (PN), 58.1% of the studied patients. Both MSH3 and MSH6 genes were significantly down-regulated in the presence of high grade PN toxicity ≥ 2 (p = 0.034 and 0.01); diarrhea toxicity (p = 0.02 and 0.008); dyspnea (p = 0.01 and 0.016) respectively and bone pain (p = 0.024 for MSH6 only). Conclusion Dysregulated expression of MMR GENES [MSH3and MSH6] can be implicated in paclitaxel—induced toxicity experienced by some cancer breast patients. |
| first_indexed | 2024-03-11T12:44:12Z |
| format | Article |
| id | doaj.art-e194cb0ebeaf428e899c5536f6b01935 |
| institution | Directory Open Access Journal |
| issn | 2314-7253 |
| language | English |
| last_indexed | 2024-03-11T12:44:12Z |
| publishDate | 2023-10-01 |
| publisher | SpringerOpen |
| record_format | Article |
| series | Future Journal of Pharmaceutical Sciences |
| spelling | doaj.art-e194cb0ebeaf428e899c5536f6b019352023-11-05T12:09:47ZengSpringerOpenFuture Journal of Pharmaceutical Sciences2314-72532023-10-01911710.1186/s43094-023-00549-2Down-regulation of MSH3 and MSH6 genes in female breast cancer patients receiving taxane-based therapyHanaa R. M. Attia0Dina F. Ayoub1Shereen H. Abd El-Aziz2Mai M. Abdel Wahed3Safa N. Abd El-Fattah4Mahmoud A. Abdel-Monem5Thanaa M. Rabah6Mahmoud M. Kamel7Amany Helal8Mona Hamed Ibrahim9Medical Research and Clinical Studies Division, Clinical and Chemical Pathology Department, Centre of Excellence, National Research CentreMedical Research and Clinical Studies Division, Clinical and Chemical Pathology Department, Centre of Excellence, National Research CentreMedical Research and Clinical Studies Division, Clinical and Chemical Pathology Department, Centre of Excellence, National Research CentreMedical Research and Clinical Studies Division, Clinical and Chemical Pathology Department, Centre of Excellence, National Research CentreMedical Research and Clinical Studies Division, Clinical and Chemical Pathology Department, Centre of Excellence, National Research CentreMedical Research and Clinical Studies Division, Medical Biochemistry Department, Centre of Excellence, National Research CentreMedical Research and Clinical Studies Division, Community Medicine Research Department, National Research CentreClinical Pathology Department, National Cancer Institute, Cairo UniversityBaheya Centre of Early Detection and Treatment of Breast CancerMedical Research and Clinical Studies Division, Clinical and Chemical Pathology Department, Centre of Excellence, National Research CentreAbstract Background The DNA in each cell in our body is constantly in danger of becoming damaged. Most DNA damage gets repaired straight away via many different proteins encoded by DNA—repair genes. MSH3 and MSH6 are pivotal DNA repair genes maintaining human genome integrity. Dysregulated expression of such genes has its implications resulting in developing of adverse reactions in cancer breast patients receiving taxanes. Cancer chemotherapy with some of taxane class of agents are associated with significant neurotoxicity, arthralgias and myalgias that may offset the therapeutic benefits of taxane use. Our aim is to identify gene expression pattern of MSH3 and MSH6 DNA mismatch repair genes in female breast cancer patients who develop adverse reactions to taxane-based therapy. One hundred and five patients with histologically proven breast cancer who received paclitaxel (PTX) as a single agent or combination therapy have been enrolled along with a group of 50 females with benign breast lesions serving as controls.Gene expression studies of mismatch repair genes (MMR) genes; MSH3 and MSH6; have been performed by real-time PCR. Patients were divided into groups according to the determined type/grade of PTX-based toxicity and fold changes of both genes were estimated. Results In the present work both MMR genes showed significantly lower expression in all the studied patients compared to benign cases as a control group. Toxicity findings were encountered in 75.2% of the studied patient cohort. The most common observed type of toxicity was peripheral neuropathy (PN), 58.1% of the studied patients. Both MSH3 and MSH6 genes were significantly down-regulated in the presence of high grade PN toxicity ≥ 2 (p = 0.034 and 0.01); diarrhea toxicity (p = 0.02 and 0.008); dyspnea (p = 0.01 and 0.016) respectively and bone pain (p = 0.024 for MSH6 only). Conclusion Dysregulated expression of MMR GENES [MSH3and MSH6] can be implicated in paclitaxel—induced toxicity experienced by some cancer breast patients.https://doi.org/10.1186/s43094-023-00549-2Mismatch repair genesBreast cancerTaxane-based therapyToxicity prediction |
| spellingShingle | Hanaa R. M. Attia Dina F. Ayoub Shereen H. Abd El-Aziz Mai M. Abdel Wahed Safa N. Abd El-Fattah Mahmoud A. Abdel-Monem Thanaa M. Rabah Mahmoud M. Kamel Amany Helal Mona Hamed Ibrahim Down-regulation of MSH3 and MSH6 genes in female breast cancer patients receiving taxane-based therapy Future Journal of Pharmaceutical Sciences Mismatch repair genes Breast cancer Taxane-based therapy Toxicity prediction |
| title | Down-regulation of MSH3 and MSH6 genes in female breast cancer patients receiving taxane-based therapy |
| title_full | Down-regulation of MSH3 and MSH6 genes in female breast cancer patients receiving taxane-based therapy |
| title_fullStr | Down-regulation of MSH3 and MSH6 genes in female breast cancer patients receiving taxane-based therapy |
| title_full_unstemmed | Down-regulation of MSH3 and MSH6 genes in female breast cancer patients receiving taxane-based therapy |
| title_short | Down-regulation of MSH3 and MSH6 genes in female breast cancer patients receiving taxane-based therapy |
| title_sort | down regulation of msh3 and msh6 genes in female breast cancer patients receiving taxane based therapy |
| topic | Mismatch repair genes Breast cancer Taxane-based therapy Toxicity prediction |
| url | https://doi.org/10.1186/s43094-023-00549-2 |
| work_keys_str_mv | AT hanaarmattia downregulationofmsh3andmsh6genesinfemalebreastcancerpatientsreceivingtaxanebasedtherapy AT dinafayoub downregulationofmsh3andmsh6genesinfemalebreastcancerpatientsreceivingtaxanebasedtherapy AT shereenhabdelaziz downregulationofmsh3andmsh6genesinfemalebreastcancerpatientsreceivingtaxanebasedtherapy AT maimabdelwahed downregulationofmsh3andmsh6genesinfemalebreastcancerpatientsreceivingtaxanebasedtherapy AT safanabdelfattah downregulationofmsh3andmsh6genesinfemalebreastcancerpatientsreceivingtaxanebasedtherapy AT mahmoudaabdelmonem downregulationofmsh3andmsh6genesinfemalebreastcancerpatientsreceivingtaxanebasedtherapy AT thanaamrabah downregulationofmsh3andmsh6genesinfemalebreastcancerpatientsreceivingtaxanebasedtherapy AT mahmoudmkamel downregulationofmsh3andmsh6genesinfemalebreastcancerpatientsreceivingtaxanebasedtherapy AT amanyhelal downregulationofmsh3andmsh6genesinfemalebreastcancerpatientsreceivingtaxanebasedtherapy AT monahamedibrahim downregulationofmsh3andmsh6genesinfemalebreastcancerpatientsreceivingtaxanebasedtherapy |